Trial Profile
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Zastumotide (Primary) ; AS15
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms DERMA; MAGE3-AS15-MEL-005
- Sponsors GlaxoSmithKline; GSK
- 12 May 2019 Trial has been discontinued in UK.
- 02 May 2019 This trial was completed in France, according to European Clinical Trials Database.
- 13 Jun 2018 Primary endpoint [Disease-free survival (In the gene signature-positive sub-population)] has not been met, as per the results published in the Lancet Oncology